FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 14:57:47 2024-06-25 EDT | ||
| 1.15 EUR | +2.68% |
|
| Current month | -21.23% | ||
| 1 month | -21.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 1.15 | +2.68% |
| 24-06-24 | 1.12 | -6.67% |
| 24-06-21 | 1.2 | +1.69% |
| 24-06-20 | 1.18 | -4.07% |
| 24-06-19 | 1.23 | +1.65% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 02:57 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LTY |
| ISIN | DE000JK2LTY9 |
| Date issued | 2024-02-23 |
| Strike | 569.9 $ |
| Maturity | Unlimited |
| Parity | 81.57 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.54 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.05 € |
| Spread % | 4.20% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
